Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Atea Pharmaceuticals, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +22 vs. Q1 2021
- Shares held
- 58.9M
- +6.84M (+13.1%) vs. Q1 2021
- Total value
- $1.27B
- −$1.94B (−60.5%) vs. Q1 2021
- New holders
- 38
- 43 more added
- Sold out
- 16
- 18 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AVIR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 124 | $276.4M |
| Q1 2026 | 127 | $322.8M |
| Q4 2025 | 111 | $203.5M |
| Q3 2025 | 115 | $154.2M |
| Q2 2025 | 107 | $189.7M |
| Q1 2025 | 104 | $158.3M |
| Q4 2024 | 107 | $188.7M |
| Q3 2024 | 108 | $194.0M |
| Q2 2024 | 105 | $187.7M |
| Q1 2024 | 113 | $219.6M |
| Q4 2023 | 108 | $168.3M |
| Q3 2023 | 119 | $170.6M |
| Q2 2023 | 133 | $213.3M |
| Q1 2023 | 131 | $190.2M |
| Q4 2022 | 131 | $278.1M |
| Q3 2022 | 126 | $326.8M |
| Q2 2022 | 128 | $408.7M |
| Q1 2022 | 127 | $396.6M |
| Q4 2021 | 143 | $479.2M |
| Q3 2021 | 142 | $1.99B |
| Q2 2021 | 104 | $1.27B |
| Q1 2021 | 82 | $3.20B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Atea Pharmaceuticals, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 5,368,451 | $115.3M | 1.85% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 5,615,659 | $120.6M | 7.90% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 6,411,355 | $137.7M | 5.37% | 00.0% | Unchanged |
| FMR LLC | 12,410,530 | $266.6M | 0.02% | +1,651,735+15.4% | Added |
| Bain Capital Public Equity Management II, LLC | 0 | $0 | 0.00% | −847,208−100.0% | Sold out |
| Bank Julius Baer & Co. Ltd, Zurich | 0 | $0 | 0.00% | −77,652−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −62,365−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −50,362−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −45,000−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −32,420−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −28,187−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −26,031−100.0% | Sold out |
| Athanor Capital, LP | 0 | $0 | 0.00% | −15,109−100.0% | Sold out |
| Parkwood LLC | 0 | $0 | 0.00% | −8,341−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −7,088−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −5,626−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −3,683−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −2,119−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −420−100.0% | Sold out |
| International Assets Investment Management, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |